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Summary
Background Chemokine receptors play an important role in cell migration and wound repair.
In asthma, CCR3 and 7 are expressed by airway smooth muscle (ASM) and CCR7 has been
implicated inthe development of ASM hyperplasia. Theexpression proﬁle of other chemokine
receptors by ASM and their function needs to be further explored.
ObjectiveWesoughttoinvestigateASMchemokinereceptorexpressionandfunctioninasthma.
Methods ASM cells were derived from 17 subjects with asthma and 36 non-asthmatic
controls. ASM chemokine receptor expression was assessed by ﬂow cytometry and
immunoﬂuorescence. The function of chemokine receptors expressed by more than 10% of
ASM cells was investigated by intracellular calcium measurements, chemotaxis, wound
healing, proliferation and survival assays.
Results In addition to CCR3 and 7, CXCR1, 3 and 4 were highly expressed by ASM. These CXC
chemokine receptors were functional with an increase in intracellular calcium following
ligand activation and promotion of wound healing [CXCL10 (100ng/mL) 34 2cells/high-
powered ﬁeld (hpf) vs. control 29 1; P=0.03; n=8]. Spontaneous wound healing was
inhibited by CXCR3 neutralizing antibody (mean difference 7 3cells/hpf; P=0.03; n=3).
CXC chemokine receptor activation did not modulate ASM chemotaxis, proliferation or
survival. No differences in chemokine receptor expression or function were observed between
ASM cells derived from asthmatic or non-asthmatic donors.
Conclusions Our ﬁndings suggest that the chemokine receptors CXCR1, 3 and 4 modulate
some aspects of ASM function but their importance in asthma is uncertain.
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Introduction
Asthma is characterized by typical symptoms, airway
hyperresponsiveness (AHR) and variable airﬂow obstruc-
tion, which can become ﬁxed in severe disease. In addi-
tion, there is associated airway inﬂammation, which is
usually eosinophilic, together with features of tissue
repair known as remodelling [1]. Airway remodelling in
asthma encompasses several structural changes in the
airway wall including reticular lamina and basement
membrane thickening and increased airway smooth mus-
cle (ASM) mass [2, 3]. This latter feature is due to a
combination of both ASM hyperplasia [4] and hypertro-
phy, which increases with disease severity and is asso-
ciated with ﬁxed airﬂow obstruction [2, 5].
The causeofASMhyperplasiainasthmais unknownand
is often attributed to increased proliferation. Indeed pro-
liferation is increased in ex vivo asthmatic ASM in some
studies [6, 7] but not others [8, 9], and several reports have
been unable to demonstrate increased ASM proliferation
in vivo [4, 5, 10]. An alternative explanation is that ASM or
its progenitors migrate to the ASM bundle. It is likely that
this recruitment will require a chemotactic signal arising
from the ASM. The C–C and C–X–C chemokines, in
particular, are attractive candidates as ASM chemoattrac-
tants. These ubiquitous, structurally related peptides med-
iate the chemotaxis of many cell types [11, 12]; play a key
roleinwoundrepair[13]andinregulatingcellsurvivaland
proliferation [14–17]. In asthma, ASM contributes to the
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tant source of chemokines [18]. However, in contrast to the
extensive literature on ASM-derived chemokines there is a
paucity of data describing the expression and function of
ASM chemokine receptors. To date only CCR1, 3 and 7, and
CXCR1 and 2 have been reported, but the relative contribu-
tion of these and possibly other chemokine receptors to
ASM function in asthma is uncertain [19–23].
We hypothesized that: (i) ASM cells express a range of
chemokine receptors, (ii) the pattern of expression is
different in subjects with and without asthma, (iii) the
chemokine receptors expressed are functional; promote
ASM migration and repair, and modulate cell survival and
proliferation. To test our hypothesis, we examined che-
mokine receptor expression and function using a variety
of techniques in health and disease.
Materials and methods
Subjects
Asthmatic subjects and non-asthmatic controls were re-
cruited from Leicester, UK. Subjects with asthma had a
consistent history and objective evidence of asthma, as
indicated by one or more of the following: (1) methacho-
line AHR (PC20FEV1o8mg/mL); (2) 415% improvement
in FEV1 15min after administration of 200mg of inhaled
salbutamol; or (3) 420% of maximum within-day ampli-
tude from twice daily peak expiratory ﬂow measurements
over 14 days. The study was approved by the Leicester-
shire Ethics Committees and all patients gave their written
informed consent.
Airway smooth muscle and mast cell isolation and culture
Pure ASM bundles in bronchial biopsies obtained from
ﬁbreoptic bronchoscopy (n=21, 17 asthmatic subjects,
four non-asthmatic) and additional airways isolated from
lung resection (n=32) were dissected free of surrounding
tissue. Primary ASM was cultured and characterized as
previously described [24]. The clinical characteristics of
the ASM donors are as shown in Table 1.
Human lung mast cells (HLMC) were isolated and
cultured from non-asthmatic lung (n=3) as previously
described [25].
Chemokine receptor protein expression
Flow cytometry. ASM were stained with antibodies to the
following chemokine receptors: mouse mAb CCR1, 2, 3, 4,
5 and 6, CXCR1, 2, 3, 4, 5 and 6 (R&D Systems, Abingdon,
Oxfordshire, UK), and CCR7, 9, and 10 (gift from Millen-
ium, Cambridge, MA, USA); rabbit polyclonal antibodies
CCR8 (AMS Biotechnology, Abingdon, Oxfordshire, UK)
and CX3CR1 (Chemicon, Hampshire, UK). These were
indirectly labelled with ﬂuorescein isothiocyanate (FITC),
and appropriate isotype controls were performed (mouse
mAb IgG1, IgG2a, IgG2b or mAb rabbit IgG, Dako, Stock-
port, UK), then analysed using single colour ﬂow cytome-
try on a FACScan (BD Bioscience, Oxford, UK). Chemokine
receptors with 410% expression were further examined,
excluding CCR3 and 7 as we have previously described the
ﬁndings for these receptors [21, 22].
Immunoﬂuorescence. ASM were grown to conﬂuence on
chamber slides and serum deprived for 24h. The cells were
labelled with the appropriate mAb or isotype control as
used for ﬂow cytometry, and indirectly labelled with FITC.
Cells were counterstained with 40,60-diamidino-2 pheny-
lindole (DAPI, Sigma, Gillingham, Dorset, UK).
Chemokine receptor mRNA expression
ASM chemokine receptor mRNA expression was assessed
in ASM cells from asthmatic (n=3) and non-asthmatic
donors (n=3) following incubation with poly(inosinic:cy-
tidylic) acid (poly(I:C), Sigma) vs. poly(deoxyinosinic–
deoxycytidylic) acid (poly(dI:dC), Sigma) control at
2.5ng/mL for 4h and following incubation with super-
natants from IgE/anti-IgE activated HLMC (10 10
6cells
pooled from three donors) for 6 and 24h. The proportion
of HLMC:ASM cells was 1:4. RNA expression levels of
chemokine receptors extracted from the ASM was exam-
ined using the Human Genome U133A probe array (Gen-
eChip, Affymetrix, Santa Clara, CA, USA). RNA was
prepared and analysed as described [26]. Hybridized
biotinylated cRNA was stained with streptavidin–phy-
coerythrin (Molecular Probes, Eugene, OR, USA), scanned
with a HP Gene Array Scanner (Affymetrix), and data
analysed using the GeneChip Analysis Suite 4.0/Operating
System (Affymetrix) as described Bradding et al. [26].
Functional assessment of airway smooth muscle
chemokine receptors
Calcium imaging. Changes in cytosolic Ca
21 concentra-
tion ([Ca
21]i) in ASM cells in response to appropriate
Table 1. Clinical characteristics [mean (SEM)]
Asthma Controls
Number 17 36
Gender (M/F) 8/9 25/11
Age (years) 53 (4) 65 (3)
FEV1 (L) 2.3 (0.2) 2.1 (0.1)
FEV1% predicted 77 (6) 81 (5)
FEV1/FVC (%) 67 (3) 74 (3)
FEV1, forced expiratory volume in 1s.
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tive control were measured by ratiometric imaging on
FURA-2-loaded cells using Openlab software (Improvi-
sion, Coventry, UK). This was converted to [Ca
21]i using a
calibration kit (Invitrogen Molecular Probes, Paisley,
Scotland, UK). Cells were considered to have responded
to a ligand if the increase in [Ca
21]i exceeded the mean12
standard deviations of the baseline.
Wound-healing assay. ASM cells were seeded onto eight
rectangular well plates coated with 10mg/mL ﬁbronectin
at a density of 0.25 10
6cells/well, allowed to adhere
overnight, then serum deprived in insulin/transferrin/
sodium selenite (ITS) (ITSx3; Sigma) media for 24h
before experimentation. Wounds were introduced using
a sterile 10mL pipette tip. The number of cells that
moved into the wound in the presence of chemokines
(25–300ng/mL) or ITS control media in the presence
or absence of the appropriate neutralizing antibody or
isotype control (R&D) over 6h were counted by a blinded
observer [22].
Chemotaxis assay. We used a validated chemotaxis assay
[22]. In brief, ASM cells were seeded as per the wound-
healing assay. Cells were removed by scraping between
the top of the well and a line predrawn across the width of
the well, on the underside of the plate, 22mm from the
bottom of the well. Cell debris was removed by washing
with ITS media. Blotting paper (25mm 6mm; Sigma)
was then placed along the upper edge of the well, secured
in place using silicon grease. Chemokines (12.5–200ng;
R&D) or ITS control media was impregnated onto blotting
paper from which it diffused into the media. The number
of cells that moved towards the resultant chemokine
concentration gradient were enumerated after 6h by a
blinded observer.
Cell metabolic activity. ASM cell metabolic activity was
assessed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium
inner salt (MTS) assay, according to the manufacturer’s
instructions (Promega, Southampton, UK), following in-
cubation with chemokines in 10% fetal bovine serum
(FBS) media (12.5–100ng/mL) or ITS media (100ng/mL)
or in the presence of appropriate neutralizing antibodies
and isotype controls (R&D) for 24 and 96h.
Proliferation and survival. ASM proliferation was as-
sessed using the CellTrace CFSE Cell Proliferation Kit
according to the manufacturer’s instructions (Invitrogen
Molecular Probes). Cells treated with 50mg/mL mitomycin
C (Sigma) for 3h to mitotically arrest cells at the parent
population, before re-addition of 10% FBS media, were
cultured in parallel to cells exposed to 10% FBS med-
ia 100ng/mL of chemokines for 96h.
The percentage of apoptotic ASM cells exposed to 10%
FBS media 100ng/mL of chemokines was identiﬁed by
DAPI staining of cell nuclei after 24 and 96h, and by
staining with FITC-conjugated Annexin V (1mL/200mL
binding buffer, BD Bioscience) propidium iodide (PI, 0.5
mg/mL, BD Bioscience) after 96h, before analysis on a
FACScan (BD Bioscience).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
4 (GraphPad software, San Diego, CA, USA). Data are
presented as mean SEM. Data was analysed by ANOVA
across groups and t-tests between groups. Differences
were considered significant when Po0.05.
Results
Chemokine receptor expression by airway smooth muscle
We examined the expression of chemokine receptors by
ASM using ﬂow cytometry. ASM expression was statisti-
cally signiﬁcant compared with isotype control for CCR1,
3, 4, 6, 7, CXCR1, 3, 4 and 6, and was also 410% for CCR3,
7, CXCR1, 3 and 4 (Fig. 1a). We have previously reported
expression of CCR3 and 7 by ASM [21, 22]. Example ﬂow
cytometry histograms for CXCR1, 3 and 4 are as shown in
Fig. 1b. The proportion of primary cultured ASM cells that
expressed cell surface CXCR1, 3 and 4 was not different
between those subjects with or without asthma (Fig. 1c).
Expression of these chemokine receptors was also con-
ﬁrmed by immunoﬂuorescence (Fig. 1d).
There was no difference in ASM chemokine receptor
mRNA expression between subjects with and without
asthma, in unstimulated ASM cells or following incuba-
tionwith poly(I:C)orHLMCsupernatants(datanotshown).
Airway smooth muscle CXCR1, 3 and 4 function
Calcium imaging. A transient mean increase in [Ca
21]i
was seen following activation of ASM with recombinant
CXCL8, 9, 10, 11 or 12 (100ng/mL) and bradykinin (1ng/
mL) (see Table 2). An example trace following activation
with CXCL10 is as shown in Fig. 2a.
Wound healing. Recombinant CXCL8, 10 and 12 all
promoted wound healing in a concentration-dependent
manner. The chemokine-mediated wound healing was
signiﬁcant for CXCL8 at 50ng/mL (34.6 2.7cells/high-
powered ﬁeld (hpf) vs. 27.6 2.0 in control; P=0.04;
n=4), for CXCL10 at 100ng/mL and 200 ng/mL
(33.8 1.7 and 35.0 2.2cells/hpf vs. 29.3 1.2 in control;
Po0.05; n=8), and for CXCL12 at 200ng/mL
(40.6 2.5cells/hpf vs. 34.3 1.6 in control; P=0.03;
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the response to other chemokines was similar (Fig. 2b).
The wound-healing response in the presence of ITS media
alone was signiﬁcantly reduced in the presence
of a CXCR3 neutralizing antibody (mean difference
6.6 2.9cells/hpf; P=0.03; n=3; Fig. 2b), but not CXCR1
or 4 neutralizing antibodies (data not shown). Platelet-
derived growth factor (PDGF) was included as a positive
control. PDGF-mediated wound healing was signiﬁcantly
increased compared with control. For all experiments,
combined PDGF-mediated wound healing was 38.9 1.4
vs. control 32.8 1.4cells/hpf (11 donors, mean difference
6.1 2.0cells/hpf; P=0.002).
Chemotaxis. Recombinant CXCL8, 10 or 12 (12.5–200ng)
did not mediate dose-dependent ASM chemotaxis (n=4,
P40.05). Data for CXCL12 only is shown as the response
to other chemokines was similar (Fig. 2c). As per the
wound-healing assays, PDGF was included as a positive
control for all chemotaxis assays and migration towards
PDGF was signiﬁcantly increased compared with the
control [for all experiments combined PDGF-mediated
migration (22.2 1.1cells/hpf [SEM]) vs. control
(19.1 0.8cells/hpf [SEM]) (11 donors, mean difference
3.1 1.3cells/hpf; P=0.02)].
Metabolic activity. The absorbance by formazan seen at
490nm in the MTS assay was increased in ASM after 96h
in both 10% FBS media and ITS media compared to ASM
at 0h. Recombinant CXCL8, 9, 10, 11 and 12 (12.5–100ng/
mL) had no effect on the MTS assay in the presence of FBS
media (n=6, P40.05), with no difference observed be-
tween ASM cells derived from non-asthmatic vs. asth-
matic donors. Data for CXCL11 only is shown as the
response to other chemokines was similar (Fig. 3a). In the
presence of ITS media, recombinant CXCL8, 9, 10, 11 and
12 (100ng/mL, n=4, P40.05) had no effect on the
absorbance measured at 490nm (data not shown). Incu-
bation with neutralizing antibodies to CXCR1, 3 and 4 had
no effect on the MTS assay in the presence of FBS media
compared with appropriate isotype controls (n=4,
P40.05, Fig. 3b).
Proliferation. Using the CellTrace CFSE Cell Proliferation
assay, cell proliferation was seen after 96h in the presence
of 10% FBS media compared with MMC-treated cells
(mean decrease in ﬂuorescence intensity 38.2 5.9,
Po0.01, n=6, Figs 3c and d). This was unaffected by
incubation with CXCL8–12 (100ng/mL) (n=6; Fig. 3d),
with no difference observed between ASM cells derived
Fig. 1. Chemokine receptor expression by primary cultured airway
smooth muscle (ASM) cells. (a) Chemokine receptor expression by ASM
cells assessed by ﬂow cytometry (n=6–21, Po0.05 compared with
appropriate isotype control).(b) CXCR1, 3 and4 expression by ASM cells.
Fluorescent histograms (black lines), plotted with corresponding isotype
controls (grey line). (c) Percentage expression in asthmatic (n=10) and
non-asthmatic (n=11) ASM cells. (d) Immunoﬂuorescence (nuclei
stained blue, chemokine receptor stained green; inset: isotype control).
Table 2. ASM intracellular calcium response to activation by CXCR1, 3 and 4 ligands (100ng/mL)
CXCL8 CXCL9 CXCL10 CXCL11 CXCL12 Bradykinin
Cells (n)2 5 1 9 2 6 2 3 2 6 5 1
Cells responding (%) 84 11 92 70 89 90
D[Ca
21]i (nM) in responding cells 228 44 98 162 169 64 136 61 168 79 255 16
ASM, airway smooth muscle.
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shown).
Survival. Following DAPI staining of ASM nuclei under
control conditions, a low percentage of cells (6.8 3.3%)
showed nuclear condensation and fragmentation
Fig. 2. Chemokine receptor-mediated airway smooth muscle (ASM)
wound healing and chemotaxis. (a) Representative trace illustrating the
[Ca
21]i elevation in ASM cells following addition of 100ng/mL of
CXCL10 (indicatedbyarrow).Similarresponseswere observedfor CXCL8
and 12. (b) Increased wound healing was observed for CXCL8, 10 and 12.
The ASM wound-healing response in the presence and absence of
CXCL10 and a CXCR3 neutralizing antibody (anti, 15mg/mL) or isotype
control (IC) is shown (n=3–8, Po0.05 compared with ITS). (c) CXCL8,
10 and 12 did not promote chemotaxis. Example of ASM chemotaxis
towards CXCL12 is as shown with PDGF (10ng) as a positive control
(n=6, comparisons made to ITS alone). Data are presented as mean
SEM. ITS, insulin/transferrin/sodium selenite; PDGF, platelet-derived
growth factor.
Fig. 3. Activation of CXCR1, 3 or 4 has no effect on airway smooth
muscle (ASM) cell metabolic activity or proliferation. Cell metabolic
activity in the presence of (a) fetal bovine serum (FBS) media CXCL11
(n=6, data are presented as mean SEM) and (b) CXCR1, 3 and 4
neutralizing antibodies and appropriate isotype controls (n=4, data are
presented as mean SEM), for 96h. (c) A representative histogram
illustrating CFSE ﬂuorescence in ASM cells incubated with 50mg/mL
MMC (black line) or FBS media 100ng/mL CXCL9 for 96h (dark grey
and light grey lines, respectively). (d) ASM cell proliferation was
observed after 96h, but was unaffected by incubation with CXCL8–12
(100ng/mL) (n=6, data are presented as geometric mean SEM).
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cells was unaffected by incubation with CXCL8–12
(100ng/mL) for 24 or 96h (P40.05, n=6). In marked
contrast in the presence of staurosporine (STS, 1mM, 20h),
a positive control, 99.7 0.2% of ASM cells showed
nuclear morphology characteristic of cells undergoing
apoptosis (Po0.01; n=6) (Figs 4a and b).
The above data were confirmed using annexin V/PI
staining of ASM cells. The percentage of annexin V
1/PI
 
(early apoptotic [27]) ASM cells was unaffected following
incubation with CXCL8–12 (100ng/mL) for 96h (P40.05,
n=6), the same was seen for annexin V
1/PI
1 (late
apoptotic/necrotic [27]) ASM cells (P40.05, n=6) (Figs
4c and d).
Using both DAPI and annexin V/PI staining, no differ-
ences were seen in chemokine receptor function between
cells derived from asthmatic subjects compared with non-
asthmatic controls (data not shown).
Discussion
We report here for the ﬁrst time a comprehensive study of
chemokine receptor expression by ASM. CCR3, 7, CXCR1,
3 and 4 were highly expressed, but expression was not
different between asthmatics and controls. CXCR1, 3 and
4 were functional as evidenced by increased calcium
response to ligand activation and promotion of wound
healing. However, the effect of recombinant chemokines
on wound healing was small and only inhibited by CXCR3
blockade. We have reported previously the ASM expres-
sion and function of CCR3 and 7 [21, 22]. In contrast to
our earlier ﬁndings for CCR3 and 7, activation of CXCR1,
3 and 4 did not mediate ASM migration, but consistent
with the CC chemokine receptors, stimulation of the CXC
chemokine receptors did not affect ASM proliferation or
survival.
Our ﬁndings conﬁrm that ASM express CCR1 [19], 3
[20, 21], 7 [22] and CXCR1 [23]. We now extend this panel
to include CCR4 and 6, CXCR3, 4 and 6. The chemokine
receptors that were highly expressed were CCR3, 7,
CXCR1, 3 and 4. Two previous studies have reported that
ASM express CCR3, and CCL11 a ligand of CCR3, has the
capacity to mediate ASM migration [20, 21]. ASM-derived
CCL19, a CCR7 ligand, also mediates ASM migration [22].
We report here for the ﬁrst time that the CXC chemokine
receptors may play a role, albeit minor, in tissue repair in
response to injury as assessed by the wound-healing
assay. This effect was most marked for CXCR3 as inhibi-
tion of this receptor inhibited wound healing in the
presence and absence of exogenous chemokines, the latter
indicating the involvement of ASM-derived chemokines.
Interestingly, we have previously reported that CXCL10
was expressed preferentially by asthmatic ASM in bron-
chial biopsies and ex vivo cells compared with those from
healthy control subjects [24]. This supports the view that
the CXCL10/CXCR3 axis may play a role in wound repair
and maintaining the ASM-bundle integrity. During air-
way inﬂammation ASM injury could occur due to the
release of various mediators from inﬂammatory cells and
Fig. 4. Activation of CXCR1, 3 or 4 has no effect on airway smooth
muscle (ASM) cell survival. (a) Representative photographs showing
DAPI staining of nuclear morphology in the presence of fetal bovine
serum (FBS) media or 100ng/mL CXCL8 for 96h, or STS as a positive
control. (b) Percentage of apoptotic ASM cells following culture with
CXCL8–12 (100ng/mL) or STS (1mM). (c) Dot blots illustrating percen-
tage of annexin V
1/PI
  (lower right) and annexin V
1/PI
1 (upper right)
ASM cells using two-colour ﬂow cytometry in the presence of FBS media





1 cells following culture with CXCL8–12 (100ng/mL)
(n=6, data are presented as mean SEM).
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Chemokine receptor expression and function in asthma 1689injured epithelial cells, which could result in the expres-
sion of various proteins, including chemokines, by ASM
[11, 28–30]. Use of the wound-healing assay to mimic the
ASM injury, which can occur during inﬂammation, is
validated by the fact that disruption of the ASM mono-
layer results in the release/expression of a number of
cytokines/chemokines that are also released/induced by
inﬂammatory cells [22, 24, 31, 32].
We were unable to demonstrate a chemotactic response
of ASM to the chemokines CXCL8–12, suggesting that
ASM CXC chemokine receptor expression does not con-
tribute signiﬁcantly to ASM recruitment. One previous
report showed that CXCL8, a ligand for CXCR1, was
chemotactic for ASM [23]. It is possible that the discre-
pancy between our ﬁndings and this earlier work and the
chemotaxis vs. the wound-healing assays may reﬂect the
relative sensitivity of the assays. However, we have con-
sistently demonstrated that our chemotaxis assay identi-
ﬁes a clear response to PDGF, CCL11 and CCL19, so if our
assay is too insensitive to detect a chemotactic response to
the CXC chemokines this effect is likely to be very small
and therefore of questionable biological importance.
Whether the chemokine receptors that were not highly
expressed by ASM play a role in ASM migration and
wound healing remains unknown and warrants further
investigation.
Chemokine receptors, including CXCR1, 3 and 4, have
been implicated in the regulation, both positive and
negative, of proliferation and survival in a number of cell
types [14, 16, 17]. Consequently they can play important
roles in processes such as haematopoeisis [15], inﬂamma-
tory disorders [17, 33] and the progression of cancer [14],
and provide potential therapeutic targets [34–36].
Whether chemokine receptors exert an effect on ASM
survival or proliferation is uncertain. To date we are only
aware of a single report examining this question [21] and
in this report CCR3 activation did not affect survival or
proliferation. We have extended this observation and
using a combination of techniques we have been unable
to ﬁnd a role for CXCL8–12 in either up- or down-
regulating ASM proliferation or survival.
Increased ASM mass is a characteristic feature of
asthma. The predominant mechanisms driving this ASM
hyperplasia are unclear but will be due to increased
proliferation, recruitment or prolonged survival of ASM
cells either alone or in combination. Our current ﬁndings
do not support a role for CXCR1, 3 or 4 in ASM migration,
proliferation or survival. Earlier work has implicated
CCR3 in ASM migration [20, 21]. However, recombinant
and ASM-derived CCL11 was inactivated by b-tryptase
and co-culture with mast cells [21, 37] and as mast cells
are located within the ASM bundle in asthma [24, 38, 39]
this questions the importance of ASM CCR3 activation
in disease. In contrast to the other chemokine receptors,
we have reported that the CCR7/CCL19 axis is important
for the migration of ASM cells towards mast cells and
the ASM bundle [22]. Importantly, recent evidence also
suggests a potential role for ASM progenitor recruitment;
ASM progenitors (ﬁbrocytes) are increased in number
in the ASM bundle in severe asthma and migration is in
part mediated by ASM-derived PDGF [40]. Therefore,
although ASM does express a wide panel of chemokine
receptors, their potential function in modulating ASM
hyperplasia appears to be limited, with CXCR3 and
CCR7 mediating wound repair and CCR7 promoting ASM
migration.
One potential criticism of our study is that we may have
underestimated the importance of chemokine receptor
function in ASM as we have not examined the effects
following priming with pro-inﬂammatory cytokines,
which play a role in disease, or the combined effects of
several chemokines. However, we have shown that ASM
chemokine receptor mRNA expression is not different
between ASM from asthmatic and non-asthmatic subjects
and is unaffected following incubation with poly(I:C)
or HLMC lysates which mimic viral infection and the
inﬂammatory milieu, respectively. Additionally, we have
previously examined the effect of mast cell–ASM interac-
tions on ASM migration and this has highlighted the
importance of the CCL19/CCR7 axis only [22]. We are
therefore conﬁdent that it is unlikely that we have over-
looked any biologically important effects of the other
chemokine receptors expressed by ASM in the pathogen-
esis of asthma.
In conclusion, we have described the panel of chemo-
kine receptors expressed by ASM from subjects with and
without asthma. CCR3, 7, CXCR1, 3 and 4 were the most
highly expressed receptors. Expression was not different
between health and disease. Further study of the function
of CXC chemokine receptors revealed that they are func-
tional and mediate wound repair but not migration,
proliferation or survival. This suggests that these chemo-
kine receptors may modulate some aspects of ASM func-
tion, but does not support a key role for CXCR1, 3 or 4 in
the development of ASM hyperplasia in asthma.
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